DOI: 10.1093/infdis/jiad350 ISSN:

Safety and immunogenicity of the heterologous two-dose Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in healthcare providers and frontliners of the Democratic Republic of the Congo

Ynke Larivière, Irene Garcia-Fogeda, Trésor Zola Matuvanga, Bernard Osangir, Solange Milolo, Rachel Meta, Primo Kimbulu, Cynthia Robinson, Michael Katwere, Chelsea McLean, Niel Hens, Junior Matangila, Vivi Maketa, Patrick Mitashi, Hypolite Muhindo-Mavoko, Jean-Pierre Van geertruyden, Pierre Van Damme, Hypolite Muhindo Mavoko, Junior Matangila Rika, Patrick Mitashi Mulopo, Vivi Maketa, Emmanuel Esanga Longomo, Trésor Zola Matuvanga, Solange Milolo Tshilumba, Rachel Meta, Pitchou Kasongo Bile, Daniel Kipasa Mambu, Primo Kimbulu Lumba, Rachel Meta, Michael Bojabwa Mondjo, Danoff Endbu Elunzi, Lazare Bakongo Isofefu, Lucien Nkoyi, Yves Tchuma Bisimwa, Jimmy Mpato Manga, Bienvenue Bolingo, Benedicte Liuba Balao, Rebecca Asieli Malaza, Jeanette Likinda, Guylain Mondje Bakongo, Sandra Mpia Bienga, Junior Mputu Ikomoli, Clarisse Ikuma Bampunga, Kanza Baye Nsase, Amba Boongo, Marguerite Mbenga Lolu, Elisabeth Mukundi Madinda, Patience Masinga Mbuku, Rodin Mukele Lungaba, Trésor Lipetsi Loyenga, Blandine Bokomo Belenge, Claudine Bakambo Luende, Solange Milolo Tshilumba, Emannual Esanga, Michael Bobjabwa Mondjo, Francis Ngoy Kankienza, Rachel Meta, Yves Tchuma Bisimwa, Trésor Zola Matuvanga, Maguy Issekitolo Fatuma Mpona, Likali Bofuke, Sorros, Lokuli Lokwa, Bofete Liweli, Nicolas Boya Likuwa, Jean Bakalo Mpeti, Bokongola Ifambe, Daudin Lokuli,
  • Infectious Diseases
  • Immunology and Allergy

Abstract

Background

In response to recent Ebola epidemics, vaccine development against the Zaire ebolavirus (EBOV) has been fast-tracked in the past decade. Healthcare providers and frontliners working in Ebola endemic areas are at high risk of contracting and spreading the virus.

Methods

This study assessed the safety and immunogenicity of the 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine regimen (administered at a 56-day interval) among 699 healthcare providers and frontliners taking part in a phase 2, monocentric, randomized vaccine trial in Boende, the Democratic Republic of Congo. The first participant was enrolled and vaccinated on December 18th, 2019. Serious adverse events were collected up to six months after the last received dose. The EBOV glycoprotein Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay (FANG ELISA) was used to measure the immunoglobulin G binding antibody response to the EBOV glycoprotein.

Results

The vaccine regimen was well tolerated with no vaccine-related serious adverse events reported. Twenty-one days after the second dose, an EBOV glycoprotein-specific binding antibody response was observed in 95.2% of participants.

Conclusions

The 2-dose vaccine regimen was well tolerated and led to a high antibody response among fully vaccinated healthcare providers and frontliners in Boende.

More from our Archive